RU2671897C2 - Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток - Google Patents
Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток Download PDFInfo
- Publication number
- RU2671897C2 RU2671897C2 RU2015138483A RU2015138483A RU2671897C2 RU 2671897 C2 RU2671897 C2 RU 2671897C2 RU 2015138483 A RU2015138483 A RU 2015138483A RU 2015138483 A RU2015138483 A RU 2015138483A RU 2671897 C2 RU2671897 C2 RU 2671897C2
- Authority
- RU
- Russia
- Prior art keywords
- cells
- tumor
- tim
- lag
- enriched
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 211
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 185
- 238000000034 method Methods 0.000 title claims abstract description 94
- 210000004027 cell Anatomy 0.000 claims abstract description 321
- 102000017578 LAG3 Human genes 0.000 claims abstract description 30
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims abstract 25
- 101150030213 Lag3 gene Proteins 0.000 claims abstract 25
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims abstract 25
- 239000003814 drug Substances 0.000 claims abstract 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 190
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 190
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 180
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 180
- 201000011510 cancer Diseases 0.000 claims description 50
- 241000124008 Mammalia Species 0.000 claims description 38
- 210000004881 tumor cell Anatomy 0.000 claims description 31
- 239000000427 antigen Substances 0.000 claims description 27
- 102000036639 antigens Human genes 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 230000001965 increasing effect Effects 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 10
- 230000000638 stimulation Effects 0.000 claims description 10
- 102000015696 Interleukins Human genes 0.000 claims description 8
- 108010063738 Interleukins Proteins 0.000 claims description 8
- 108010065805 Interleukin-12 Proteins 0.000 claims description 7
- 229940126638 Akt inhibitor Drugs 0.000 claims description 6
- 108090000172 Interleukin-15 Proteins 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 6
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000003197 protein kinase B inhibitor Substances 0.000 claims description 6
- -1 IL -21 Proteins 0.000 claims description 5
- 108010002586 Interleukin-7 Proteins 0.000 claims description 5
- VPVLEBIVXZSOMQ-UHFFFAOYSA-N 3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol Chemical compound NC1=CC=CC(C=2NC3=NC=NC(OC=4C=C(O)C=CC=4)=C3C=2)=C1 VPVLEBIVXZSOMQ-UHFFFAOYSA-N 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 108091033773 MiR-155 Proteins 0.000 claims description 3
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000002463 transducing effect Effects 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 151
- 230000014509 gene expression Effects 0.000 description 51
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 30
- 201000001441 melanoma Diseases 0.000 description 29
- 238000000338 in vitro Methods 0.000 description 18
- 108091008874 T cell receptors Proteins 0.000 description 14
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 14
- 230000009257 reactivity Effects 0.000 description 13
- 230000028327 secretion Effects 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 230000000735 allogeneic effect Effects 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 108010050904 Interferons Proteins 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000004186 co-expression Effects 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 5
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 5
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000000690 anti-lymphoma Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241001466804 Carnivora Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241001493546 Suina Species 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 230000001400 myeloablative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 102000007295 Mucin-3 Human genes 0.000 description 1
- 108010008701 Mucin-3 Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000032383 Soft tissue cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108010079351 Tumor Suppressor Protein p14ARF Proteins 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046799 Uterine leiomyosarcoma Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 201000007696 anal canal cancer Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000003956 middle ear cancer Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 201000007425 nasal cavity carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4272—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/51—Stomach
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771247P | 2013-03-01 | 2013-03-01 | |
| US61/771,247 | 2013-03-01 | ||
| PCT/US2013/038799 WO2014133567A1 (en) | 2013-03-01 | 2013-04-30 | Methods of producing enriched populations of tumor-reactive t cells from tumor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018136226A Division RU2808817C2 (ru) | 2013-03-01 | 2018-10-15 | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015138483A RU2015138483A (ru) | 2017-04-13 |
| RU2671897C2 true RU2671897C2 (ru) | 2018-11-07 |
Family
ID=48444601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015138483A RU2671897C2 (ru) | 2013-03-01 | 2013-04-30 | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20160010058A1 (enExample) |
| EP (2) | EP2961415B1 (enExample) |
| JP (4) | JP6416131B2 (enExample) |
| CN (1) | CN105163744A (enExample) |
| AU (4) | AU2013379772B2 (enExample) |
| CA (1) | CA2902423C (enExample) |
| ES (1) | ES2859678T3 (enExample) |
| RU (1) | RU2671897C2 (enExample) |
| WO (1) | WO2014133567A1 (enExample) |
Families Citing this family (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296832A (en) | 2005-10-18 | 2022-11-01 | Nat Jewish Health | Process of preparing red blood cells using conditionally immortalized long-term hematopoietic stem cells and erythropoietin |
| IL287311B2 (en) | 2008-05-16 | 2024-06-01 | Taiga Biotechnologies Inc | Antibodies and processes for their preparation |
| EP2318435B1 (en) | 2008-08-28 | 2015-12-23 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc |
| WO2014015312A1 (en) | 2012-07-20 | 2014-01-23 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| EP2961415B1 (en) * | 2013-03-01 | 2021-01-06 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing enriched populations of tumor-reactive t cells from tumor |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| US20170044496A1 (en) | 2014-04-10 | 2017-02-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy |
| WO2016053339A1 (en) * | 2014-10-02 | 2016-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells having antigenic specificity for a cancer-specific mutation |
| AU2014407539B2 (en) * | 2014-10-02 | 2020-10-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
| WO2016179006A1 (en) * | 2015-05-01 | 2016-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| WO2016187508A2 (en) | 2015-05-20 | 2016-11-24 | The Broad Institute Inc. | Shared neoantigens |
| WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| EP3368689B1 (en) | 2015-10-28 | 2020-06-17 | The Broad Institute, Inc. | Composition for modulating immune responses by use of immune cell gene signature |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| US11001622B2 (en) | 2015-11-19 | 2021-05-11 | The Brigham And Women's Hospital, Inc. | Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein |
| MX2018007295A (es) * | 2016-01-11 | 2019-03-28 | Armo Biosciences Inc | Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos. |
| ES3000676T3 (en) | 2016-07-07 | 2025-03-03 | Iovance Biotherapeutics Inc | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof |
| US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
| US20210292696A1 (en) | 2016-09-22 | 2021-09-23 | Corning Incorporated | Gravity flow cell culture devices, systems, and methods of use thereof |
| WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| KR20240150531A (ko) | 2016-10-26 | 2024-10-15 | 이오반스 바이오테라퓨틱스, 인크. | 냉동보존된 종양 침윤 림프구의 재자극 |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| US12227578B2 (en) | 2016-11-11 | 2025-02-18 | The Broad Institute, Inc. | Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action |
| WO2018094167A1 (en) | 2016-11-17 | 2018-05-24 | Iovance Biotherapeutics, Inc. | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same |
| CN110177758B (zh) | 2016-12-02 | 2021-10-01 | 泰加生物工艺学公司 | 纳米颗粒调配物 |
| AU2018205234B2 (en) | 2017-01-06 | 2024-09-19 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists |
| JP7664020B2 (ja) | 2017-01-06 | 2025-04-17 | アイオバンス バイオセラピューティクス，インコーポレイテッド | カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用 |
| EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| WO2018183921A1 (en) | 2017-04-01 | 2018-10-04 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
| US20200071773A1 (en) | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
| WO2019103857A1 (en) | 2017-11-22 | 2019-05-31 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
| IL270412B2 (en) | 2017-05-10 | 2025-03-01 | Iovance Biotherapeutics Inc | Expansion of infiltrating lymphocytes from liquid samples and their medical uses |
| EP3622092A4 (en) | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| WO2018215936A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
| TW201919662A (zh) | 2017-06-05 | 2019-06-01 | 美商艾歐凡斯生物治療公司 | 對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法 |
| US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| WO2019014581A1 (en) | 2017-07-14 | 2019-01-17 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| JP6731114B2 (ja) | 2017-08-03 | 2020-07-29 | タイガ バイオテクノロジーズ，インク． | メラノーマの処置のための方法および組成物 |
| WO2019070755A1 (en) | 2017-10-02 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
| WO2019084055A1 (en) | 2017-10-23 | 2019-05-02 | Massachusetts Institute Of Technology | CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS |
| WO2019094955A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas |
| WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
| AU2018368786B2 (en) | 2017-11-17 | 2025-05-22 | Iovance Biotherapeutics, Inc. | TIL expansion from fine needle aspirates and small biopsies |
| US20210369775A1 (en) | 2017-12-15 | 2021-12-02 | Iovance Biotherapeutics, Inc. | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof |
| US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
| MX2020007046A (es) | 2018-01-08 | 2020-09-07 | Iovance Biotherapeutics Inc | Procesos para generar productos de linfocitos infiltrantes de tumores (til) enriquecidos para celulas t especificas de antigenos tumorales. |
| WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| PT3775165T (pt) | 2018-03-29 | 2024-07-17 | Iovance Biotherapeutics Inc | Processos para produção de linfócitos infiltrantes de tumor e utilizações dos mesmos em imunoterapia |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| MA52533A (fr) | 2018-04-27 | 2021-03-03 | Iovance Biotherapeutics Inc | Procédé en circuit fermé pour l'amplification et l'edition de gènes de lymphocytes d'infiltration des tumeurs et leurs utilisations en immunothérapie |
| US12473532B2 (en) | 2018-05-10 | 2025-11-18 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| TW202031273A (zh) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療 |
| CA3112599A1 (en) | 2018-09-20 | 2020-03-26 | Iovance Biotherapeutics, Inc. | Expansion of tils from cryopreserved tumor samples |
| WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
| SG11202104615VA (en) | 2018-11-05 | 2021-06-29 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| WO2020096989A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
| EP3877511A1 (en) | 2018-11-05 | 2021-09-15 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
| SG11202104630PA (en) | 2018-11-05 | 2021-06-29 | Iovance Biotherapeutics Inc | Selection of improved tumor reactive t-cells |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| WO2020131547A1 (en) | 2018-12-19 | 2020-06-25 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| JP2022527117A (ja) | 2019-04-08 | 2022-05-30 | タイガ バイオテクノロジーズ，インク． | 免疫細胞の凍結保存のための組成物および方法 |
| WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| EP3969041A4 (en) | 2019-05-14 | 2023-05-10 | Taiga Biotechnologies, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| US20220226464A1 (en) | 2019-05-28 | 2022-07-21 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| EP3998082A4 (en) * | 2019-07-10 | 2024-02-07 | National Cancer Center | SPECIFIC MARKER FOR IDENTIFYING T CELLS SPECIFICALLY ATTACKING CANCER CELLS |
| WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| CN110484504B (zh) * | 2019-08-28 | 2022-10-14 | 复旦大学附属中山医院 | 一种用于免疫治疗原发性肝细胞肝癌的细胞亚群及其制备方法 |
| US20220298501A1 (en) | 2019-08-30 | 2022-09-22 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| JP6878544B2 (ja) * | 2019-10-02 | 2021-05-26 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法 |
| JP7340144B2 (ja) * | 2019-10-02 | 2023-09-07 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法 |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| CA3155727A1 (en) | 2019-10-25 | 2021-04-29 | Cecile Chartier-Courtaud | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US20210130438A1 (en) * | 2019-10-28 | 2021-05-06 | The Broad Institute, Inc. | Pan-cancer t cell exhaustion genes |
| CA3161104A1 (en) | 2019-12-11 | 2021-06-17 | Cecile Chartier-Courtaud | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
| BR112022011795A2 (pt) | 2019-12-20 | 2022-08-30 | Instil Bio Uk Ltd | Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| AU2021228701A1 (en) * | 2020-02-28 | 2022-09-15 | KSQ Therapeutics, Inc. | Methods for activation and expansion of tumor infiltrating lymphocytes |
| JP2020143057A (ja) * | 2020-04-01 | 2020-09-10 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法 |
| JP2023524639A (ja) | 2020-04-22 | 2023-06-13 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 患者特異的免疫療法用細胞の製造調整システム及び調整方法 |
| JP2023524108A (ja) * | 2020-05-04 | 2023-06-08 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 改良された腫瘍反応性ｔ細胞の選択 |
| TW202208617A (zh) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | 用於產生腫瘤浸潤性淋巴球的過程及其在免疫療法中的用途 |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| EP4225330A1 (en) | 2020-10-06 | 2023-08-16 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| EP4259164A1 (en) | 2020-12-11 | 2023-10-18 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
| JP2024500403A (ja) | 2020-12-17 | 2024-01-09 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球によるがんの治療 |
| WO2022133140A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| AU2021400069A1 (en) | 2020-12-18 | 2023-07-06 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
| JP2023554425A (ja) | 2020-12-18 | 2023-12-27 | インスティル バイオ （ユーケイ） リミテッド | 腫瘍浸潤リンパ球の処理 |
| EP4271791A2 (en) | 2020-12-31 | 2023-11-08 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
| CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
| CN117279506A (zh) | 2021-03-05 | 2023-12-22 | 艾欧凡斯生物治疗公司 | 肿瘤储存及细胞培养组合物 |
| CA3212439A1 (en) | 2021-03-19 | 2022-09-22 | Michelle SIMPSON-ABELSON | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
| AU2022246174A1 (en) | 2021-03-25 | 2023-09-14 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
| WO2022225981A2 (en) | 2021-04-19 | 2022-10-27 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
| TW202327631A (zh) | 2021-07-28 | 2023-07-16 | 美商艾歐凡斯生物治療公司 | 利用腫瘤浸潤性淋巴球療法與ｋｒａｓ抑制劑組合治療癌症患者 |
| WO2023039488A1 (en) | 2021-09-09 | 2023-03-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
| EP4404969A1 (en) | 2021-09-24 | 2024-07-31 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
| US20230187042A1 (en) | 2021-10-27 | 2023-06-15 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| US20250032618A1 (en) | 2021-11-10 | 2025-01-30 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| EP4469066A1 (en) | 2022-01-28 | 2024-12-04 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
| EP4507704A1 (en) | 2022-04-15 | 2025-02-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
| WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
| WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| EP4612277A1 (en) | 2022-11-04 | 2025-09-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
| CN120584182A (zh) | 2022-11-21 | 2025-09-02 | 艾欧凡斯生物治疗公司 | 肿瘤浸润淋巴细胞扩增的二维过程及其疗法 |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
| WO2024151885A1 (en) | 2023-01-13 | 2024-07-18 | Iovance Biotherapeutics, Inc. | Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy |
| WO2025015318A2 (en) | 2023-07-13 | 2025-01-16 | Iovance Biotherapeutics, Inc. | Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes |
| WO2025019790A1 (en) | 2023-07-19 | 2025-01-23 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc |
| WO2025059533A1 (en) | 2023-09-13 | 2025-03-20 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025101484A1 (en) | 2023-11-06 | 2025-05-15 | Iovance Biotherapeutics, Inc. | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
| WO2025171182A1 (en) | 2024-02-08 | 2025-08-14 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2367468C2 (ru) * | 2003-11-19 | 2009-09-20 | Мерк Патент Гмбх | БЕЛКИ, ОТНОСЯЩИЕСЯ К СЕМЕЙСТВУ Всl-2, И ИХ ФРАГМЕНТЫ И ИХ ПРИМЕНЕНИЕ У ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ |
| US20130052642A1 (en) * | 2010-01-26 | 2013-02-28 | Universidade De Santiago De Compostela | Method for the identification and purification of human naturally occurring regulatory t cells (ntregs) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| WO2003028630A2 (en) * | 2001-10-04 | 2003-04-10 | Genetics Institute Llc. | Methods and compositions for modulating interleukin-21 receptor activity |
| WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| JPWO2007018198A1 (ja) * | 2005-08-09 | 2009-02-19 | 国立大学法人 熊本大学 | Ｈｌａ−ａ２陽性者用ｈｓｐ１０５由来癌拒絶抗原ペプチド及びこれを含む医薬 |
| WO2012129201A1 (en) * | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| EP2961415B1 (en) * | 2013-03-01 | 2021-01-06 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing enriched populations of tumor-reactive t cells from tumor |
-
2013
- 2013-04-30 EP EP13722922.5A patent/EP2961415B1/en active Active
- 2013-04-30 ES ES13722922T patent/ES2859678T3/es active Active
- 2013-04-30 WO PCT/US2013/038799 patent/WO2014133567A1/en not_active Ceased
- 2013-04-30 AU AU2013379772A patent/AU2013379772B2/en active Active
- 2013-04-30 CN CN201380075798.XA patent/CN105163744A/zh active Pending
- 2013-04-30 CA CA2902423A patent/CA2902423C/en active Active
- 2013-04-30 JP JP2015560159A patent/JP6416131B2/ja active Active
- 2013-04-30 US US14/771,615 patent/US20160010058A1/en not_active Abandoned
- 2013-04-30 EP EP20217061.9A patent/EP3821898A1/en active Pending
- 2013-04-30 RU RU2015138483A patent/RU2671897C2/ru active
-
2018
- 2018-04-26 JP JP2018085761A patent/JP6788629B2/ja active Active
- 2018-12-04 AU AU2018274874A patent/AU2018274874B2/en active Active
-
2020
- 2020-08-21 AU AU2020220209A patent/AU2020220209A1/en not_active Abandoned
- 2020-10-30 JP JP2020182208A patent/JP7181917B2/ja active Active
-
2022
- 2022-09-20 AU AU2022235535A patent/AU2022235535B2/en active Active
- 2022-11-18 JP JP2022185113A patent/JP7653962B2/ja active Active
-
2023
- 2023-01-06 US US18/093,902 patent/US20230265387A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2367468C2 (ru) * | 2003-11-19 | 2009-09-20 | Мерк Патент Гмбх | БЕЛКИ, ОТНОСЯЩИЕСЯ К СЕМЕЙСТВУ Всl-2, И ИХ ФРАГМЕНТЫ И ИХ ПРИМЕНЕНИЕ У ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ |
| US20130052642A1 (en) * | 2010-01-26 | 2013-02-28 | Universidade De Santiago De Compostela | Method for the identification and purification of human naturally occurring regulatory t cells (ntregs) |
Non-Patent Citations (3)
| Title |
|---|
| INOZUME T. et al., Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T-cells, J. Immunother., 2010, v.33, is.9, p.956-964. * |
| INOZUME T. et al., Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T-cells, J. Immunother., 2010, v.33, is.9, p.956-964. PRIETO P.A., Enrichment of CD8+ Cells From Melanoma Tumor-infiltrating Lymphocyte Cultures Reveals Tumor Reactivity for Use in Adoptive Cell Therapy, J. Immunother., 2010, v.33, is.5, p.547-556. * |
| PRIETO P.A., Enrichment of CD8+ Cells From Melanoma Tumor-infiltrating Lymphocyte Cultures Reveals Tumor Reactivity for Use in Adoptive Cell Therapy, J. Immunother., 2010, v.33, is.5, p.547-556. * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018136226A (ru) | 2019-03-21 |
| US20160010058A1 (en) | 2016-01-14 |
| AU2013379772A1 (en) | 2015-09-17 |
| EP3821898A1 (en) | 2021-05-19 |
| CA2902423A1 (en) | 2014-09-04 |
| WO2014133567A1 (en) | 2014-09-04 |
| EP2961415A1 (en) | 2016-01-06 |
| AU2018274874A1 (en) | 2019-02-28 |
| AU2013379772B2 (en) | 2018-09-20 |
| AU2018274874B2 (en) | 2020-05-21 |
| ES2859678T3 (es) | 2021-10-04 |
| JP2021019634A (ja) | 2021-02-18 |
| JP6416131B2 (ja) | 2018-10-31 |
| JP2016509839A (ja) | 2016-04-04 |
| JP6788629B2 (ja) | 2020-11-25 |
| RU2015138483A (ru) | 2017-04-13 |
| JP2018148898A (ja) | 2018-09-27 |
| JP7653962B2 (ja) | 2025-03-31 |
| AU2020220209A1 (en) | 2020-09-10 |
| CA2902423C (en) | 2021-06-29 |
| AU2022235535A1 (en) | 2022-10-13 |
| JP7181917B2 (ja) | 2022-12-01 |
| EP2961415B1 (en) | 2021-01-06 |
| CN105163744A (zh) | 2015-12-16 |
| US20230265387A1 (en) | 2023-08-24 |
| JP2023018043A (ja) | 2023-02-07 |
| AU2022235535B2 (en) | 2025-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2671897C2 (ru) | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток | |
| JP7029617B2 (ja) | 末梢血から腫瘍反応性ｔ細胞の濃縮された集団を作製する方法 | |
| EP3154567B1 (en) | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy | |
| RU2808817C2 (ru) | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток | |
| KR20240170059A (ko) | 면역 세포 치료를 위한 종양 반응성이 있는 t 세포 집단을 활성화시켜 증식하는 방법 | |
| HK40053468A (en) | Methods of producing enriched populations of tumor-reactive t cells from tumor | |
| HK40026892A (en) | Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer | |
| HK40035292B (zh) | 从外周血中产生肿瘤反应性t细胞富集群的方法 | |
| HK40035292A (en) | Methods of producing enriched populations of tumor reactive t cells from peripheral blood | |
| HK40055747A (en) | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy | |
| HK1236418A1 (en) | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy | |
| HK1236418B (en) | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy |